As GLP-1 RAs have demonstrated cardiovascular protective effects in large randomized trials involving individuals with overweight or obesity, it is possible that these benefits could be especially advantageous for postmenopausal women with PCOS, a group at heightened risk during this period (80). Here, GCG is linked to obesity disorder.